Chemical characterization and in vitro cyto- and genotoxicity of ‘legal high’ products containing Kratom (Mitragyna speciosa)
- 529 Downloads
Kratom is a popular ‘legal high’ mainly constituted by alkaloids extracted from the Mitragyna speciosa plant with mitragynine (MG) as the dominant active substance. The increasing use of Kratom for recreational purposes has alerted risk assessment bodies of the lack of information on the real composition and its potential health risks. The present study aimed to determine and compare the MG composition of 13 commercial products of Kratom sold online and in “smartshops”, by gas chromatography–mass spectrometry. For the first time, the cytotoxicity induced by pure MG and Kratom, extracts was evaluated in in vitro models of human intestinal (Caco-2) and neuronal (SH-SY5Y) cells after 6 and 24 h. Genotoxicity was also evaluated in intestinal Caco-2 cells following 24 h of exposure to subtoxic concentrations using the comet assay. The obtained results revealed an inconsistency between the information (‘power’) provided in labels and the MG content. Cytotoxicity tests revealed a concentration-dependent decrease in cell viability in both cellular models, with the SH-SY5Y cells being more sensitive to the Kratom extracts. The resin and the ‘powered extracts’ were the most cytotoxic samples, with IC50 values significantly lower than the leaf extracts and pure MG (P < 0.0001 vs. leaf extracts and MG). In addition, significant DNA damage was observed in Caco-2 cells exposed to these extracts but not to pure MG, which suggests that other substances present in the extracts or interactions involving Kratom components might be responsible for the observed effects.
KeywordsKratom GC–MS Cytotoxicity Genotoxicity Caco-2 cell line SH-SY5Y cell line
This work received financial support from the European Union (FEDER funds through COMPETE) and National Funds (FCT, Fundação para a Ciência e Tecnologia) through project Pest-C/EQB/LA0006/2013.
Compliance with ethical standards
Conflict of interest
There are no financial or other relations that could lead to a conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.EMCDDA (2012) The EMCDDA annual report 2012: the state of the drugs problem in Europe. http://www.emcdda.europa.eu/. Accessed Mar 2015
- 2.EMCDDA (2013) European Drug Report 2013: trends and developments. http://www.emcdda.europa.eu/edr2013. Accessed Mar 2015
- 3.EMCDDA (2014) European Drug Report 2014: trends and developments. http://www.emcdda.europa.eu/edr2014. Accessed Mar 2015
- 7.Gong F, Gu H-P, Xu Q-T, Kang W-Y (2012) Genus Mitragyna: ethnomedicinal uses and pharmacological studies. Phytopharmacology 3:263–272Google Scholar
- 9.EMCDDA (2014) Kratom (Mitragyna speciosa). http://www.emcdda.europa.eu/publications/drug-profiles/kratom. Accessed Mar 2015
- 12.Hassan Z, Muzaimi M, Navaratnam V, Yusoff NHM, Suhaimi FW, Vadivelu R, Vicknasingam BK, Amato D, von Hörsten S, Ismail NIW, Jayabalan N, Hazim AI, Mansor SM, Mullen CP (2013) From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev 37:138–151CrossRefPubMedGoogle Scholar
- 17.Brossi A, Cordell GA (1992) The alkaloids: chemistry and pharmacology. Academic Press, WalthamGoogle Scholar
- 18.O’Mahory Carey S (2010) Psychoactive substances: a guide to ethnobotanical plants and herbs, synthetic chemicals, compounds and products. Drug Education Officer, Substance Misuse Service, Clonmel. http://lenus.ie/hse/handle/10147/112933. Accessed Mar 2015
- 23.Roche KM, Hart K, Sangalli B, Lefberg J, Bayer M (2008) Kratom: a case of a legal high. Clin Toxicol 46:598Google Scholar
- 32.Portuguese Government (2013) Decreto-Lei no. 54/2013. Diário da República 75Google Scholar
- 33.EMA (1995) Validation of analytical procedures: text and methodology. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002662.pdf. Accessed Mar 2015
- 34.Fraga S, Faria H, Soares ME, Duarte JA, Soares L, Pereira E, Costa-Pereira C, Teixeira JP, Lourdes Bastos M, Carmo H (2013) Influence of the surface coating on the cytotoxicity, genotoxicity and uptake of gold nanoparticles in human HepG2 cells. J Appl Toxicol 33:1111–1119CrossRefPubMedGoogle Scholar
- 35.Chan KB, Pakiam C, Rahim RA (2005) Psychoactive plant abuse: the identification of mitragynine in ketum and in ketum preparations. B Narcotics 57:249–256Google Scholar
- 39.Sanagi MM, Ayob MFM, Omar N, Ibrahim WAW, Hussain I (2013) Determination of mitragynine for the identification of mitragyna species in Kedah (Malaysia) by gas chromatography-mass spectrometry. Der Pharma Chem 5:131–138Google Scholar
- 48.Araújo AM, Valente MJ, Carvalho M, da Silva DD, Gaspar H, Carvalho F, de Lourdes Bastos M, Guedes de Pinho P (2015) Raising awareness of new psychoactive substances: chemical analysis and in vitro toxicity screening of ‘legal high’packages containing synthetic cathinones. Arch Toxicol 89:757–771CrossRefPubMedGoogle Scholar
- 50.Ghazali AR, Abdullah R, Ramli N, Rajab NF, Ahmad-Kamal MS, Yahya NA (2011) Mutagenic and antimutagenic activities of Mitragyna speciosa Korth extract using Ames test. J Med Plants Res 5:1345–1348Google Scholar
- 52.Costa DLMG, Rinaldo D, Varanda EA, de Sousa JF, Nasser ALM, Silva ACZ, Baldoqui DC, Vilegas W, dos Santos LC (2014) Flavonoid detection in hydroethanolic extract of Pouteria torta (Sapotaceae) leaves by HPLC-DAD and the determination of its mutagenic activity. J Med Food 17:1103–1112CrossRefPubMedPubMedCentralGoogle Scholar
- 53.Tamouou VJ, Kuete V (2014) Mutagenicity and carcenogenicity of African medicinal plants. In: Kuete V (ed) Toxicological survey of African medicinal plants. Elsevier, Amsterdam, pp 277–282Google Scholar